SUMMARY
Diabetes mellitus is a chronic disease that damages the entire body. Organ by organ, physiological function is lost. Scientists around the world are trying to find methods to halt the global rise of this condition. Glucose homeostasis is regulated by several hormones — primarily insulin, amylin, glucagon, and glucagon-like peptide-1 (GLP-1). Since the discovery of amylin in 1986, the role of the β-cell in glucose homeostasis has become more significant. Amylin exerts insulin-like glucose-lowering effects, inhibits glucagon secretion, and induces a feeling of satiety. It regulates eating behavior and contributes to weight reduction. The hypothalamic satiety center interacts with the hormone amylin, which also works synergistically with leptin. This functional interaction between amylin and leptin hormones is already well established.
Keywords: insulin, amylin, glucose, β-cell, hypothalamus, obesity

---

REFERENCES

1. Аметов А.С. Роль бета-клеток в регуляции гомеостаза глюкозыв норме и при сахарном диабете 2 типа // Сахарный диабет, - 2008 - 11(4), - с. 6-11.
2. Barg S., Elliason L., Renstrom E. et al. A subject of 50 secretory granules in close contact with a-type Са2+ channels accounts for first-phase insulin secretion in mouse p-sells. Kinetics of insulin release in health and Type 2 Diabetes // Diabetes, - 2002, V. 51, suppl. I, - p. 74. https://doi.org/10.2337/diabetes.51.2007.s74.
3. Klöppel G., Löhr M., Habich K. et al. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited // Surv Synth Pathol Res., - 1985, 4(2), - p. 110-25. https://doi.org/10.1159/000156969.
4. Cerasi E., Ktorza A. Plasticité anatomique et fonctionnelle des cellules bêta du pancréas endocrine et diabète de type 2 [Anatomical and functional plasticity of pancreatic beta-cells and type 2 diabetes] // Med Sci (Paris), - 2007, 23(10), - p. 885-94. https://doi.org/10.1051/medsci/20072310885.
5. Cooper G.J., Willis A.C., Clark A., et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients // Proc Natl Acad Sci U S A, - 1987, 84(23), - p. 8628-32. https://doi.org/10.1073/pnas.84.23.8628.
6. Westermark P. Amyloid in the islets of Langerhans: thoughts and some historical Aspects Ups // J Med Sci., - 2011. 116(2), p. 81-89. https://doi.org/10.3109/03009734.2011.573884.
7. Волков В.П. Новые панкреатические гормоны: Амилин // Медицина и фармакология, - 2014, №11 12), - с.1.
8. Boccia L., Gamakharia S., Coester B. et al. Amylin brain circuitry. Peptides. 2020; 132:170366. https://doi.org/10.1016/j.peptides.2020.170366.
9. Yoshihara C., Tokita K., Maruyama T. et al. Calcitonin receptor signaling in the medial preoptic area enables risk-taking maternal care // Cell Rep., - 2021, 35(9), - p. 109204. https://doi.org/10.1016/j.celrep.2021.109204.
10. Trevaskis JL., Wittmer C., Athanacio J. et al. Amylin/leptin synergy is absent in extreme obesity and not restored by calorie restriction-induced weight loss in rats // Obes Sci Pract., - 2016, 2(4), - p. 385-391. https://doi.org/10.1002/osp4.62.
11. Rushing P.A., Hagan M.M., Seeley R.J. et al. Amylin: a novel action in the brain to reduce body weight // Endocrinology, - 2000, 141(2), - p. 850-3. doi:10.1210/endo.141.2.7378.
12. Lutz T.A., Coester B., Whiting L. et al. Amylin Selectively Signals Onto POMC Neurons in the Arcuate Nucleus of the Hypothalamus // Diabetes, - 2018, 67(5), - p. 805-817. https://doi.org/10.2337/db17-1347.
13. Reidelberger R.D., Haver A.C., Arnelo U. et al. Amylin receptor blockade stimulates food intake in rats // Am J Physiol Regul Integr Comp Physiol., - 2004, 287(3), - p. R568-74. https://doi.org/10.1152/ajpregu.00213.2004.
14. Li Z., Kelly L., Heiman M. et al. Hypothalamic Amylin Acts in Concert with Leptin to Regulate Food Intake // Cell Metab., - 2015, 22(6), - p. 1059-67. doi: 10.1016/j.cmet.2015. 10.012.
15. Bhowmick D.C., Singh S., Trikha S. et al. The molecular physiopathogenesis of islet amyloidosis // Handb Exp Pharmacol, - 2018, 245, - p. 271-312. doi:10.1007/164_2017_62.
16. Ryan G., Briscoe T.A., Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes // Drug Des Devel Ther., - 2009, 2, - p. 203-14. https://doi.org/10.2147/dddt.s3225.
17. Christoffersen B.Ø., Sanchez-Delgado G., John L.M. et al. Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss // Obesity (Silver Spring), - 2022, 30(4), - p. 841-857. https://doi.org/10.1002/oby.23374.
18. Jorsal T., Rungby J., Knop F.K. et al. GLP-1 and Amylin in the Treatment of Obesity // Curr Diab Rep., - 2016, 16(1), - p. 1. https://doi.org/ 10.1007/s11892-015-0693-3.
19. Potes C.S., Turek V.F., Cole R.L. et al. Noradrenergic neurons of the area postrema mediate amylin's hypophagic action // Am J Physiol Regul Integr Comp Physiol., - 2010, 299(2), - p. R623-31. https://doi.org/10.1152/ajpregu.00791.2009.
20. Mietlicki-Baase E.G., McGrath L.E., Koch-Laskowski K. et al. Amylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior // Neuropharmacology, - 2017, 123, - p. 67-79. https://doi.org/10.1016/j.neuropharm.2017.05.024.
21. Simonsen L., Lau J., Kruse T. et al. Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls // PLoS ONE. – 2022, 17(3), - p. e0264974. https://doi.org/10.1371/journal.pone.0264974.
22. Enebo L.B., Berthelsen K.K., Kankam M. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial // Lancet, - 2021, 397(10286), - p. 1736-1748. https://doi.org/10.1016/S0140-6736(21)00845-X.
23. Kruse T., Hansen JL., Dahl K. et al. Development of Cagrilintide, a Long-Acting Amylin Analogue // J Med Chem., 2021. 64(15), p, 11183-11194. doi:10.1021/acs.jmedchem. 1c00565.